Failure to Monitor Residents on Anticoagulant Therapy for Bleeding
Summary
The facility failed to monitor the use of anticoagulant therapy for two sampled residents, including monitoring for signs and symptoms of bleeding. One resident was receiving Heparin injections for DVT prophylaxis and had diagnoses including hydronephrosis with renal and ureteral calculous obstruction, cirrhosis of the liver, and pancytopenia. The resident’s MDS indicated moderately impaired cognitive skills for daily decision making and dependence in multiple activities of daily living. During observation, multiple areas of discoloration were noted on both upper extremities, and the resident stated he was taking an anticoagulant and had bruises on his arms and legs. For this resident, the physician orders showed Heparin was administered over several days, but the MDS nurse stated there was no order for monitoring signs and symptoms of bleeding during that period. The nurse also stated the MAR did not contain documented evidence that the resident was monitored for bleeding, and the care plan did not include anticoagulant-related interventions. Facility staff stated that if a resident was started on anticoagulant therapy, a care plan should be in place right away to include monitoring for signs and symptoms of bleeding and side effects. The second resident had diagnoses including metabolic encephalopathy, Afib, and hypertension, and the MDS indicated moderately impaired cognitive skills and dependence in multiple areas of care. The physician order included Eliquis 2.5 mg twice daily for Afib. Although the resident had a care plan for anticoagulant therapy that directed staff to administer the medication, monitor for side effects and effectiveness every shift, and monitor for signs and symptoms of bleeding every shift, the MDS nurse stated there was no documented evidence in the MAR or nurses’ progress notes that this monitoring was performed. The facility’s anticoagulation clinical protocol stated staff and the physician would monitor for possible complications in individuals being anticoagulated, and the nurse would discuss excessive bruising, hematuria, hemoptysis, or other evidence of bleeding with the physician before the next scheduled dose.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.